Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity

Anthony R White, Tai Du, Katrina M Laughton, Irene Volitakis, Robyn A Sharples, Michel E Xilinas, David Edmund Hoke, R M Damian Holsinger, Genevieve Evin, Robert A Cherny, Andrew F Hill, Kevin Jeffrey Barnham, Qiao-Xin Li, Ashley I Bush, Colin Louis Masters

Research output: Contribution to journalArticleResearchpeer-review

268 Citations (Scopus)


Biometals play an important role in Alzheimer disease, and recent reports have described the development of potential therapeutic agents based on modulation of metal bioavailability. The metal ligand clioquinol (CQ) has shown promising results in animal models and small phase clinical trials; however, the actual mode of action in vivo has not been determined. We now report a novel effect of CQ on amyloid beta-peptide (Abeta) metabolism in cell culture. Treatment of Chinese hamster ovary cells overexpressing amyloid precursor protein with CQ and Cu(2+) or Zn(2+) resulted in an approximately 85-90 reduction of secreted Abeta-(1-40) and Abeta-(1-42) compared with untreated controls. Analogous effects were seen in amyloid precursor protein-overexpressing neuroblastoma cells. The secreted Abeta was rapidly degraded through up-regulation of matrix metalloprotease (MMP)-2 and MMP-3 after addition of CQ and Cu(2+). MMP activity was increased through activation of phosphoinositol 3-kinase and JNK. CQ and Cu(2+) also promoted phosphorylation of glycogen synthase kinase-3, and this potentiated activation of JNK and loss of Abeta-(1-40). Our findings identify an alternative mechanism of action for CQ in the reduction of Abeta deposition in the brains of CQ-treated animals and potentially in Alzheimer disease patients.
Original languageEnglish
Pages (from-to)17670 - 17680
Number of pages11
JournalJournal of Biological Chemistry
Issue number26
Publication statusPublished - 2006

Cite this